Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rohto Pharmaceutical CoFRA:UC1 -1.53%73 Return-on-Tangible-Equity is 11.23% as of Mar. 2026, which is 11% below its 10-year median of 12.60. GuruFocus rates FRA:UC1 with a GF Score™ of 73/100 and a GF Value™ of €18.58 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,881 Consumer Packaged Goods companies, Rohto Pharmaceutical Co ranks better than 74.22% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Rohto Pharmaceutical Co's annualized net income for the quarter that ended in Mar. 2026 was €130 Mil. Rohto Pharmaceutical Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €1,159 Mil. Therefore, Rohto Pharmaceutical Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 11.23%.
The historical rank and industry rank for Rohto Pharmaceutical Co's Return-on-Tangible-Equity or its related term are showing as below:
FRA:UC1'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 7.78 Med: 12.6 Max: 16.74
Current: 16.74
During the past 13 years, Rohto Pharmaceutical Co's highest Return-on-Tangible-Equity was 16.74%. The lowest was 7.78%. And the median was 12.60%.
FRA:UC1's Return-on-Tangible-Equity is ranked better than 74.22% of 1881
companies
in the Consumer Packaged Goods industry
Industry Median: 7.78
vs FRA:UC1: 16.74
Rohto Pharmaceutical Co (FRA:UC1) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Rohto Pharmaceutical Co Return-on-Tangible-Equity Related Terms
Rohto Pharmaceutical Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Rohto Pharmaceutical Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rohto Pharmaceutical Co Return-on-Tangible-Equity Chart
FRA:UC1 vs PG, CL, KVUE: Return-on-Tangible-Equity Comparison
For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rohto Pharmaceutical Co Return-on-Tangible-Equity vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Rohto Pharmaceutical Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 11.23% mean?
Rohto Pharmaceutical Co (FRA:UC1) has a Return-on-Tangible-Equity of 11.23% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Rohto Pharmaceutical Co and its competitors. This is 11% below median its historical median of 12.60. Over the past decade, Rohto Pharmaceutical Co's Return-on-Tangible-Equity has ranged from 7.78 to 16.74. According to the industry distribution chart, Rohto Pharmaceutical Co ranks #485 out of 1881 companies in the Consumer Packaged Goods industry, placing it in the top 25.8%.
Is Rohto Pharmaceutical Co's Return-on-Tangible-Equity too high?
Rohto Pharmaceutical Co's current Return-on-Tangible-Equity of 11.23% is 11% below median its 10-year median of 12.60. Over the past 10 years, this metric has ranged from a low of 7.78 to a high of 16.74. The Consumer Packaged Goods industry median Return-on-Tangible-Equity is 7.78. Rohto Pharmaceutical Co's value of 11.23% is 44.3% above this industry median. Based on the distribution chart, Rohto Pharmaceutical Co ranks #485 out of 1881 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, Rohto Pharmaceutical Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rohto Pharmaceutical Co's Return-on-Tangible-Equity compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Rohto Pharmaceutical Co ranks #485 out of 1881 companies for Return-on-Tangible-Equity. This puts Rohto Pharmaceutical Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.78. Rohto Pharmaceutical Co's value of 11.23% is 44.3% above this benchmark. Historically, Rohto Pharmaceutical Co's own Return-on-Tangible-Equity has ranged from 7.78 to 16.74 over the past decade. While the company's 10-year median is 12.60 vs. the industry median of 7.78, Rohto Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Consumer Packaged Goods company?
The median Return-on-Tangible-Equity among Consumer Packaged Goods companies is 7.78, based on 1,881 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rohto Pharmaceutical Co's current Return-on-Tangible-Equity of 11.23% is 44.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Rohto Pharmaceutical Co and its competitors. For the Consumer Packaged Goods industry, the median Return-on-Tangible-Equity is 7.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rohto Pharmaceutical Co's current Return-on-Tangible-Equity is 11.23%, which is 11% below median its own 10-year median of 12.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rohto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co (FRA:UC1) is currently considered Significantly Undervalued. The stock's GF Value™ is €18.58, compared to a current price of €12.90 — trading 30.6% below its estimated fair value. The current Return-on-Tangible-Equity is 11.23%, which is 11% below median its 10-year median of 12.60 and 44.3% above the Consumer Packaged Goods industry median of 7.78. Rohto Pharmaceutical Co's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Rohto Pharmaceutical Co (FRA:UC1), the current Return-on-Tangible-Equity is 11.23% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rohto Pharmaceutical Co (FRA:UC1) Overvalued in 2026?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co stock appears to be undervalued.
The current stock price of €12.90 is trading 30.6% below its estimated GF Value™ of €18.58.
GuruFocus considers Rohto Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for FRA:UC1:
Return-on-Tangible-Equity: 11.23% (11% below median its 10-year median of 12.60)
GF Value™: €18.58 vs. price of €12.90 (30.6% below fair value)
Industry Position: 44.3% above the Consumer Packaged Goods median (#485 of 1881)
No single metric tells the full story. See the FRA:UC1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rohto Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of health and beauty care products. The company operates through four reportable segments: Japan, America, Europe, and Asia. Each segment manufactures and sells products related to eye care (such as eye drops and eyewash), skin care (including dermatological medications, lip balm, sunscreen, and functional cosmetics), oral medication (such as gastrointestinal and herbal medicines, and supplements), and other products such as in-vitro diagnostic reagents. It generates the majority of its revenue from Japan.
73GF Score
Get the complete analysis for FRA:UC1
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UC1 has been successfully added to your 
